Vanguard Portfolio Management’s Cardlytics CDLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-17,220
Closed -$181K 3159
2026
Q1
$181K Buy
+17,220
New +$168K ﹤0.01% 3053

Other funds holding CDLX

Vanguard Portfolio Management's CDLX Position: Q2 2026 in Review

Vanguard Portfolio Management sold out of Cardlytics (CDLX) in Q2 2026, closing a stake of 17,220 shares — an estimated $181K sold.

Vanguard Portfolio Management first reported a position in CDLX in Q1 2026 and held it in 1 quarter. The position peaked at $181K in Q1 2026. 41 funds tracked by Wall St. Rank hold CDLX as of Q2 2026.

  • Vanguard Portfolio Management reported no remaining Cardlytics position as of Q2 2026 after selling out during the quarter.
  • Vanguard Portfolio Management sold 17,220 Cardlytics shares in Q2 2026, an estimated $181K.
  • Vanguard Portfolio Management first reported a position in Cardlytics in Q1 2026 and held it in 1 quarter.
  • Vanguard Portfolio Management's Cardlytics position peaked at $181K in Q1 2026.
  • 41 funds tracked by Wall St. Rank held Cardlytics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.